Cartesian Therapeutics, Inc.
General ticker "RNAC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $227.4M (TTM average)
Cartesian Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -19.3%.
Estimated limits based on current volatility of 7.6%: low 8.66$, high 10.08$
Factors to consider:
- Total employees count: 66 as of 2024
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.27$, 10.17$]
- 2026-12-31 to 2027-12-31 estimated range: [2.81$, 8.74$]
Financial Metrics affecting the RNAC estimates:
- Negative: with PPE of -2.4 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -4.41 < Investing cash flow per share per price, % of -3.03
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term RNAC quotes
Long-term RNAC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $26.00MM | $38.91MM | $2.80MM |
| Operating Expenses | $112.42MM | $82.81MM | $146.20MM |
| Operating Income | $-86.42MM | $-43.90MM | $-143.41MM |
| Non-Operating Income | $-152.29MM | $-33.24MM | $3.91MM |
| Interest Expense | $2.83MM | $0.00MM | $0.00MM |
| R&D Expense | $71.26MM | $45.10MM | $58.03MM |
| Income(Loss) | $-238.71MM | $-77.14MM | $-139.50MM |
| Taxes | $-19.00MM | $0.29MM | $-9.19MM |
| Net Income(Loss)* | $-219.71MM | $-77.42MM | $-130.30MM |
| Stockholders Equity | $-440.18MM | $-6.80MM | $-126.24MM |
| Assets | $305.05MM | $435.02MM | $296.41MM |
| Operating Cash Flow | $-51.16MM | $-23.67MM | $-73.94MM |
| Capital expenditure | $0.21MM | $9.09MM | $5.45MM |
| Investing Cash Flow | $34.61MM | $-8.74MM | $-5.45MM |
| Financing Cash Flow | $-13.14MM | $168.43MM | $-8.05MM |
| Earnings Per Share** | $-42.49 | $-2.99 | $-5.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.